Host: |
HEK293 |
Note: |
STRICTLY FOR FURTHER RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
Recombinant-Mouse EPO-protein was developed from hek293. For use in research applications. |
Conjugation: |
Unconjugated |
Formulation: |
Lyophilised from 0.2 µm filtered PBS solution pH7.4. |
Dilution Range: |
Spin the vial and reconstite in distilled water to a concentration not less than 0.1 mg/mL. This can then be diluted into other buffers. |
Storage Instruction: |
The lyophilized protein is stable for at least 1 year from date of receipt at-20°C. NA |
Endotoxin: |
Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than 0.1 ng/µg (1EU/µg). NA |
Immunoreactivity: |
The activity was determined by its ability to bind in functional ELISA assay. NA |
Gene Symbol: |
Epo |
Gene ID: |
13856 |
Uniprot ID: |
EPO_MOUSE |
Immunogen Region: |
Mature chain |
Immunogen: |
DNA sequence encoding the mature chain of Mouse erythropoietin EPO including a C-terminal His tag was expressed in HEK293 Cells. NA |
Immunogen Sequence: |
APPRLICDSR VLERYILEAK EAENVTMGCA EGPRLSENIT VPDTKVNFYA WKRMEVEEQA IEVWQGLSLL SEAILQAQAL LANSSQPPET LQLHIDKAIS GLRSLTSLLR VLGAQKELMS PPDTTPPAPL RTLTVDTFCK LFRVYANFLR GKLKLYTGEV NA |
Tissue Specificity | Produced by kidney or liver of adult mammals and by liver of fetal or neonatal mammals. |
Function | Hormone involved in the regulation of erythrocyte proliferation and differentiation and the maintenance of a physiological level of circulating erythrocyte mass. Binds to EPOR leading to EPOR dimerization and JAK2 activation thereby activating specific downstream effectors, including STAT1 and STAT3. |
Protein Name | Erythropoietin |
Database Links | Reactome: R-MMU-9027276Reactome: -MMU-9027284 |
Cellular Localisation | Secreted |
Alternative Protein Names | Erythropoietin proteinEpo protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance